Searched for
LALPATHLABS
Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...- Smallcaps continue to draw domestic flows, stock selection key: Sandip SabharwalIndian equity markets show resilience post-election results. Market expert Sandip Sabharwal notes that governance and policy continuity are...
- Forget the noise: These 54 smallcap stocks attracted FII buying in March quarterForeign institutional investors are strategically buying into beaten-down smallcap stocks in India, increasing stakes in 54 companies despi...
- Mutual funds bought 505 smallcap stocks in March crash. Two weeks later, they're winning bigIndian mutual funds bought smallcap stocks in March when retail investors sold. This strategy paid off as the Nifty Smallcap 250 index rose...
- Stocks to buy in 2026 for long term: Time Technoplast, Dr Lal PathLabs among 5 recommendations that could give 10-40% returnWe have collated a list of recommendations from top brokerage firms from ETNow and other sources.
- Dr. Lal PathLabs shares turn ex-bonus tomorrow for 1:1 issue, last day to buy for eligibilityAs per the corporate filings, the company will issue one fully paid-up bonus equity share of face value Rs 10 for every one existing fully ...
- Dr Lal Path Labs announces 1:1 bonus issue, declares Rs 7/share interim dividendDiagnostics services company Dr Lal Path Labs on Friday announced an interim dividend of Rs 7 per equity share for the financial year 2025-...
- Polycab, Dr Lal PathLabs among 5 stocks with long buildup
- Dr Lal PathLabs Q1 FY24 net profit rises 44% to Rs 84 croreDr Lal PathLabs' Q1FY24 net profit surged 44% YoY to INR84 crore due to the rise in non-Covid testing and higher realisations, while non-Co...
- Dr Lal Path Labs cracks 9% on weak Q2 showThe company’s revenue from operations, however, grew 7.1% to Rs 533.8 crore during the period under review, from Rs 498.4 crore in the corr...
- Dr Lal Path Labs Q2 PAT declines 25 pc to Rs 72.4 crThe company had posted a profit after tax (PAT) of Rs 96.3 crore in the year-ago period, it said in a BSE filing.Its revenue from operation...
- Day Trade Guide: 2 stock recommendations for FridayA sustained trade beyond 17,400 will extend the uptrend taking Nifty50 higher to the levels of 17,500-17,600. However, failing to trade and...
- Dr Lal PathLabs Q2 results: Net profit up 11% at Rs 96 croreOperating revenue of the company increased by 15.4 per cent in Q2 FY22 to Rs 498.4 crore as compared with Rs 431.9 crore in Q2 FY21, Dr Lal...
- Dr Lal Path Labs buys Suburban Diagnostics in all-cash dealThe development comes amid consolidation and heightened investor interest in the diagnostics sector due to the Covid-19 pandemic.
- Why you should take Prediabetes seriously, renowned experts and doctors discussExclusive session to emphasise risks, diagnosis, tests and cure for Prediabetes as an esteemed panel of doctors and experts deliberate on t...
- Valuation of diagnostic stocks unsustainable: Sandip Sabharwal"I think the valuation across the board is excessive, be it Metropolis or Dr Lal Path Labs. Thyrocare is slightly less expensive, but it is...
- Banking giants ICICI Bank, SBI poised for strong moveAs far as individual stocks are concerned, inclination would be more towards mid-cap counter.
- Nomura upgrades Dr Lal PathLabs to 'buy' from 'neutral'The brokerage said growth in recent times in Dr Lal PathLabs has been hit by demonetisation but it remains constructive on long term growth...
- Dr Lal Path Labs eying revenues of Rs 350 cr in FY12Dr Lal Path Labs, which operates Asia's largest diagnostics centre in the capital, runs 70 laboratories across the country.
- TA Associates buys minority stake in Lal PathLabsTA Associates made a minority investment in Dr Lal PathLabs by purchasing half of Sequoia Capital’s stake in the company for an undisclosed...
Load More
